Evidence map›Paper›PMID 32550498›Full record

ArticlemicroPublication biology2020

Oncogenic

Briana Brown Rackley, Evan Kiely, Chang-Soo Seong, Manali Rupji, Melissa Gilbert-Ross

Abstract read
In one paragraph

Article in microPublication biology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Briana Brown RackleyDepartment of Hematology and Medical Oncology, Emory University School of Medicine.
Evan KielyDepartment of Hematology and Medical Oncology, Emory University School of Medicine.
Chang-Soo SeongDepartment of Hematology and Medical Oncology, Emory University School of Medicine.
Manali RupjiBiostatistics and Bioinformatics Shared Resource, Winship Cancer Institute of Emory University.
Melissa Gilbert-RossDepartment of Hematology and Medical Oncology, Emory University School of Medicine.

Funding

Winship Cancer Institute Cancer Center Support GrantP30CA138292 · NCI · EMORY UNIVERSITY · PI Suresh S Ramalingam · 2009 to 2026
$47.5M
Project 3: Targeting Bax signaling to overcome treatment resistance in NSCLCP50CA217691 · NCI · EMORY UNIVERSITY · PI SICA, GABRIEL LARKIN · 2019 to 2024
$10.1M
Drosophila Transgenic RNAi Resource ProjectR01GM084947 · NIGMS · HARVARD MEDICAL SCHOOL · PI PERRIMON, NORBERT · 2008 to 2019
$9.8M
Defining Early Escape Strategies in LKB1 Mutant Lung Cancer S1R01CA201340 · NCI · EMORY UNIVERSITY · PI GILBERT-ROSS, MELISSA, MARCUS, ADAM I. · 2016 to 2020
$2.0M
NCI NIH HHS P30 CA138292NCI NIH HHS P50 CA217691NCI NIH HHS R01 CA201340NIGMS NIH HHS R01 GM084947
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Identifiers

PMID32550498
PMCPMC7252341

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.